NVAX trade ideas
Comparison chart $OCGN with $NVAX Tribune News Service
New Delhi, March 10
India’s indigenous COVID-19 vaccine COVAXIN is no longer to be used in clinical trial mode and has got the nod of national experts to be used under the normal restricted emergency use authorisation route, just like the Serum Institute manufactured Covishield.
The move entails a huge boost to the indigenous Covid vaccine sector and the ICMR and Bharat Biotech, the joint developers of COVAXIN.
The restricted emergency use authorisation to COVAXIN had been held up in early January as the vaccine’s phase 3 efficacy data was unavailable till then and its efficiency was yet to be established though the vaccine was safe and immunogenic in early phase 1 and 2 trials.
The drug regulator had at that time approved the use of COVAXIN in clinical trial mode until efficacy data came.
With Bharat Biotech presenting interim phase 3 data showing 81 per cent efficacy for COVAXIN and Lancet also declaring the vaccine safe and immunogenic with minimum side effects based on phase 2 trial data published yesterday, the subject experts at the Central Drug Standard Control Organisation today reviewed COVAXIN data for two hours and recommended that the vaccine be brought out of the use in clinical trial mode and placed in the category of restricted emergency use.
This means beneficiaries of COVAXIN would not need to be followed up closely after administration of the jab, something that was mandatory when the vaccine was permitted for use in clinical trial mode.
COVAXIN export will also get a boost with the move.
I reopened my NVAX short with <120 targetAfter liquidating my 175 puts yesterday, as described in the linked idea,
I am shorting it again via 3/12 120 puts. My bet will win if it has another run down next week.
As a reminder, I don't do Yolo's, so my strategy assumes that I am going to be wrong and lose money most of the time.
I am careful with the size of my bets and this one is no exception.
My lucky 14x profit on NVAX and why I am still ready to short itI covered my shorts on NVX once 150 was reached. See my linked idea.
I did this trade with puts. Which were mostly crazy expensive at the time, but I was able to get 175 3/05 Puts for about $1.50 a couple of weeks ago.
I sold them today for an average price of 20.5, which gives this trade a 14x result.
Looking at the chart and at fundamentals, I will be looking for a short reentry. Let's see if I get a chance! There seems to be good support at 70-80 level.
Closing Nvax Shortcould still close gap, but hit most of the move, staying neutral, looking for long entry
NVAX Just Completed its Head & Shoulders. Target: $150ishAlright, just look at the chart. Chances are this is a major trend reversal.
2021 Actual Trade: NVAX +122% ProfitsNVAX provides desirable sideway patterns both from September-November 2020 and December-January 2021 so it gave us a chance to study NVAX from technical and fundamental perspectives.
After we accumulated twice in January 2021, NVAX was discovered and shot to the sky. We took a quick profit first. Then, COVID-19 began to decline, which caused NVAX to slow down also. We decided to close it completely. The highest point we got from NVAX was +122% profits.
It's unbelievable where this is sitting right now..This is a nice example of how following who's involved can lead to excellent opportunities. Just look at $SAVA. In the Christmas months of 2019, multiple insiders were seen purchasing $100's of thousands worth of shares immediately before the share price skyrocketed several hundred percent. Fast forward 13 months later, and the price broke $100..
Still, many times, you question whether these sharp intraday rallies are the product of market manipulation, as they always seem to happen immediately before heavy sell offs, but who knows..
NVAX coming back 400+ soonHey guys so NVAX had a nice bounce today from its open at 240 and closed at 273.98. It was a solid day I'm not too happy about the volume though due to it being pretty low. The stock is not going to have a tremendous move if there is no volume. We need to have above average volume to see a nice spike above 300 again. Now with the EU news coming possibly end of this week or next week I believe NVAX is going to skyrocket. I am still staying strong with my bullish target of 400 by end of February due to the amount of volume and buy orders we are going to have with the incredible EU deal. Even if EU does not come out this week we still are very oversold on the indicators and have destroyed Pfizer’s new SA variant numbers which show only 20% effectiveness on the new variant. Ours is 60% if you forgot, so we are in good shape right now do not be intimidated by shorts and hold strong!!
NVAX Saw this stock ripping on a Friday afternoon. Took a big position and scaled out the next day to lower cost basis to 106. I traded this stock last year for a great run so I was familiar with what it can do.
NVAX going to 450 late February!! I see a massive spike coming in really soon with NVAX, with the pullback continuing probably till 278 I see an explosion coming!! Around 450 a share is where I see NVAX landing! With RSI, MACD, and William % showing oversold levels I see a reverse coming next week to the uptrend. I hope I am right let us see.
Target price for Novavax..?Novavax is getting ready to test its all time high at 300, but it could go further.
On April 15th 2020, I made the first call on MRNA, NVAX, and INO, to be the companies which will produce COVID-19 vaccine.After 10 months 2 out of 3 have COVID-19 vaccine on the market!
Ever since MRNA has had 468% and NVAX made a decent 1240% gain just in 9 months
This is what I see for NVAX for 2021 huge gains are coming inNVAX stock has had a massive explosion from January where the stock hit 294 a share yesterday. Now I had a prediction that NVAX would break 300 a share by March I think it will be much sooner now. With all the orders and revenue stream that will be produced in 2021, we could see total revenue of 16 billion dollars. I am firmly confident we can reach the same market cap as Moderna as our vaccine is currently more effective and we have more vaccine orders. You may think I am crazy when I predict 1200 a share in a year but if you do the math and see the data it becomes quite convincing. I am not gonna even think about selling until this stock reaches over 500 which I believe could come in May.
Where NVAX is headingBeautiful inverse H&S. Looking for that $350-ish for potential sell or consolidation.
NVAX: Rally nearing conclusion? Possible correction on the way.NASDAQ:NVAX
After an impressive rally, NVAX is lingering in overbought territory which means it's probably time for a correction. Price is approaching Fibonacci levels that typically indicate a reversal or correction. Additionally, there appears to be bearish divergence and my experimental indicator based on TD sequential is signaling that the rally may be is overextended. $300 is psychological resistance - price may test and break that level after market open then quickly retreat to support. NYSE:PFE earning call is today so that could possibly have some ripple into $NVAX price action. There are more point to be made for both the bear and bull case but this is just a quick analysis of how this may play out in the short term
COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 TrialNovavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants
Strong efficacy in Phase 3 UK trial with over 50% of cases attributable to the now-predominant UK variant and the remainder attributable to COVID-19 virus
Clinical efficacy demonstrated in Phase 2b South Africa trial with over 90% of sequenced cases attributable to prevalent South Africa escape variant
NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase 3 clinical trial conducted in the United Kingdom (UK).
Novavax also announced successful results of its Phase 2b study conducted in South Africa.
Significant progress on PREVENT-19 Clinical Trial in US and Mexico
finance.yahoo.com
NVAX 156%After 5 months of consolidation (and 1 month of breakout/consolidation), NVAX looks as if it is ready to pump...we go from a descending wedge breakout to an ascending triangle...bullish divergengence in the macd...as well as a bullish crossover in the macd in positive territory...we should wait for another drop to the 50 day ema ($117)...however, that may not happen...target is $300 (156%)...IT'S YOUR MONEY, DYOR!!
NVAX created a reversal patternAs we can see the price is bouncing up and down creating a sideways direction. This week gives me great hope for a reversal pattern to break above the Darvas Box.
